Receptor, Fibroblast Growth Factor, Type 2
"Receptor, Fibroblast Growth Factor, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor which contains three extracellular IMMUNOGLOBULIN I-SET DOMAINS and is expressed as two isoforms. One receptor isoform is expressed in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform is expressed mainly by EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in craniosynostotic syndromes (e.g., APERT SYNDROME; and CROUZON SYNDROME).
| Descriptor ID |
D051497
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.178 D12.776.543.750.630.441 D12.776.543.750.750.400.370.750
|
| Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 2- Receptor, Fibroblast Growth Factor, Type 2
- BEK Fibroblast Growth Factor Receptor
- BEK Protein Tyrosine Kinase
- Bek Fgf Receptor Kinase
- Fibroblast Growth Factor Receptor 2
- Bek-Related Fibroblast Growth Factor-Receptor-1
- Bek Related Fibroblast Growth Factor Receptor 1
- Fibroblast Growth Factor Receptors 2
- FGFR2 Protein
- CD332 Antigen
- Antigen, CD332
- BEK Fibroblast Growth Factor Receptor Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 2 [D08.811.913.696.620.682.725.400.178]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.630.441]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.750.400.370.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 2".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Profiles.
-
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients. JCO Precis Oncol. 2025 Jan; 9:e2400712.
-
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284.
-
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary. Mol Ther. 2024 Oct 02; 32(10):3650-3668.
-
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024; 20(36):2811-2822.
-
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 02; 80(2):322-334.
-
Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023 10 17; 4(10):101204.
-
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.
-
The combined action of the intracellular regions regulates FGFR2 kinase activity. Commun Biol. 2023 07 14; 6(1):728.